Table 3

Antidrug antibodies and pharmacokinetics after mota-YTE and motavizumab treatment

Treatment group (drug and dose)	Titer^{^a}	Positive titer [study day(s)]	CL (liters/day)^{^b}	t_1/2 (days)^{^b}
Mota-YTE
0.3 mg/kg^{^c}	1:120	14	NC	NC
3 mg/kg	1:60	150, 210, 240	0.0512	106
3 mg/kg	≤1:30^{^d}	210	0.0322	111
15 mg/kg	1:120–1:240	150, 210, 240	0.0774	85.2
Motavizumab
3 mg/kg	1:30	150, 210	0.522	18.9
3 mg/kg	1:120	150, 210, 240	0.336	15.7
15 mg/kg	1:60–1:120	150, 210, 240	0.453	13.2

↵a Each titer represents one subject.
↵b Data correspond to the study day with the first positive result. CL, serum clearance; NC, not calculated; t_1/2, terminal phase half-life.
↵c One subject in the 0.3 mg/kg mota-YTE group and one in the 30 mg/kg mota-YTE group with anti-mota-YTE ADA had detectible titers predose (suggesting that these are false positives), and they are not included in table.
↵d Borderline positive.